Reviva Pharmaceuticals Holdings Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 14

Employees

  • Stock Symbol
  • RVPH

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.35
  • (As of Monday Closing)

Reviva Pharmaceuticals Holdings General Information

Description

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 10080 North Wolfe Road
  • Suite SW3-200
  • Cupertino, CA 95014
  • United States
+1 (408)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 10080 North Wolfe Road
  • Suite SW3-200
  • Cupertino, CA 95014
  • United States
+1 (408)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Reviva Pharmaceuticals Holdings Stock Performance

As of 16-Nov-2026, Reviva Pharmaceuticals Holdings’s stock price is $0.35. Its current market cap is $4.59M with 13.1M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.35 $0.35 $0.26 - $15.40 $4.59M 13.1M 29.7K -$0.48

Reviva Pharmaceuticals Holdings Financials Summary

As of 30-Sep-2026, Reviva Pharmaceuticals Holdings has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (13,584) 19,418 78,832 139,031
Revenue 0 0 0 0
EBITDA (11,839) (20,144) (30,242) (39,609)
Net Income (11,310) (19,865) (29,919) (39,261)
Total Assets 18,557 15,923 15,503 23,700
Total Debt 44 407 458 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Reviva Pharmaceuticals Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Reviva Pharmaceuticals Holdings‘s full profile, request access.

Request a free trial

Reviva Pharmaceuticals Holdings Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commer
Drug Discovery
Cupertino, CA
14 As of 2025

Boston, MA
 

Washington, DC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Reviva Pharmaceuticals Holdings Competitors (5)

One of Reviva Pharmaceuticals Holdings’s 5 competitors is Praxis (Drug Discovery), a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Praxis (Drug Discovery) Formerly VC-backed Boston, MA
Vanda Pharmaceuticals Formerly VC-backed Washington, DC
Axsome Therapeutics Formerly VC-backed New York, NY
Alkermes Formerly VC-backed Dublin, Ireland
Definium Therapeutics Formerly VC-backed New York, NY
You’re viewing 5 of 5 competitors. Get the full list »

Reviva Pharmaceuticals Holdings Patents

Reviva Pharmaceuticals Holdings Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026136179-A1 Method for treating negative symptoms of schizophrenia Pending 16-Dec-2024
EP-4687910-A1 Brilaroxazine liposome composition Pending 30-Mar-2023
US-20260021104-A1 Brilaroxazine liposome composition Pending 30-Mar-2023
WO-2024206692-A1 Brilaroxazine liposome composition Inactive 30-Mar-2023
EP-4687911-A1 Method for treating psoriasis Pending 30-Mar-2023 A61K31/538
To view Reviva Pharmaceuticals Holdings’s complete patent history, request access »

Reviva Pharmaceuticals Holdings Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Reviva Pharmaceuticals Holdings Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Reviva Pharmaceuticals Holdings‘s full profile, request access.

Request a free trial

Reviva Pharmaceuticals Holdings Acquisitions (1)

Reviva Pharmaceuticals Holdings’s most recent deal was a Merger/Acquisition with Tenzing Acquisition. The deal was made on 14-Dec-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tenzing Acquisition 14-Dec-2020 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Reviva Pharmaceuticals Holdings’s complete acquisitions history, request access »

Reviva Pharmaceuticals Holdings ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Reviva Pharmaceuticals Holdings’s complete esg history, request access »

Reviva Pharmaceuticals Holdings FAQs

  • When was Reviva Pharmaceuticals Holdings founded?

    Reviva Pharmaceuticals Holdings was founded in 2006.

  • Where is Reviva Pharmaceuticals Holdings headquartered?

    Reviva Pharmaceuticals Holdings is headquartered in Cupertino, CA.

  • What is the size of Reviva Pharmaceuticals Holdings?

    Reviva Pharmaceuticals Holdings has 14 total employees.

  • What industry is Reviva Pharmaceuticals Holdings in?

    Reviva Pharmaceuticals Holdings’s primary industry is Drug Discovery.

  • Is Reviva Pharmaceuticals Holdings a private or public company?

    Reviva Pharmaceuticals Holdings is a Public company.

  • What is Reviva Pharmaceuticals Holdings’s stock symbol?

    The ticker symbol for Reviva Pharmaceuticals Holdings is RVPH.

  • What is the current stock price of Reviva Pharmaceuticals Holdings?

    As of 16-Nov-2026 the stock price of Reviva Pharmaceuticals Holdings is $0.35.

  • What is the current market cap of Reviva Pharmaceuticals Holdings?

    The current market capitalization of Reviva Pharmaceuticals Holdings is $4.59M.

  • Who are Reviva Pharmaceuticals Holdings’s competitors?

    Praxis (Drug Discovery), Vanda Pharmaceuticals, Axsome Therapeutics, Alkermes, and Definium Therapeutics are competitors of Reviva Pharmaceuticals Holdings.

  • What is Reviva Pharmaceuticals Holdings’s annual earnings per share (EPS)?

    Reviva Pharmaceuticals Holdings’s EPS for 12 months was -$0.48.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process